Methyltransferase like 13 (METTL13), also known as faint expression in normal tissues, aberrant overexpression in tumors (FEAT), localized at 1q24.3, was originally identified as an inhibitor of nuclear apoptosis in rat brains.5 Studies reported that METTL13 expression was upregulated in liver cancer,6 breast cancer, lung cancer,7 and head and neck cancers.8 Liu et al9 showed that METTL13-mediated K55 methylation of eukaryotic translation elongation factor-1A (eEF1A) promoted tumorigenicity. Here, METTL13 is linked to breast carcinoma.